Cargando…
Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER)
Oxycodone DETERx(®) (Collegium Pharmaceutical Inc, Canton, Massachusetts) is an extended‐release, microsphere‐in‐capsule, abuse‐deterrent formulation designed to retain its extended‐release properties after tampering (eg, chewing/crushing). This randomized, double‐blind, placebo‐controlled, triple‐d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363337/ https://www.ncbi.nlm.nih.gov/pubmed/27669664 http://dx.doi.org/10.1002/jcph.833 |
_version_ | 1782517144649465856 |
---|---|
author | Kopecky, Ernest A. Fleming, Alison B. Levy‐Cooperman, Naama O'Connor, Melinda M. Sellers, Edward |
author_facet | Kopecky, Ernest A. Fleming, Alison B. Levy‐Cooperman, Naama O'Connor, Melinda M. Sellers, Edward |
author_sort | Kopecky, Ernest A. |
collection | PubMed |
description | Oxycodone DETERx(®) (Collegium Pharmaceutical Inc, Canton, Massachusetts) is an extended‐release, microsphere‐in‐capsule, abuse‐deterrent formulation designed to retain its extended‐release properties after tampering (eg, chewing/crushing). This randomized, double‐blind, placebo‐controlled, triple‐dummy study evaluated the oral abuse potential of intact and chewed oxycodone DETERx capsules compared with crushed immediate‐release oxycodone. Subjects with a history of recreational opioid use who were nondependent/nontolerant to opioids were enrolled. Treatments included intact oxycodone DETERx (high‐fat, high‐calorie meal and fasted), chewed oxycodone DETERx (high‐fat, high‐calorie meal and fasted), crushed immediate‐release oxycodone (fasted), and placebo (high‐fat, high‐calorie meal). Plasma samples were collected to determine pharmacokinetic parameters. The primary endpoint was drug liking at the moment; other endpoints included drug effects questionnaire scores, Addiction Research Center Inventory/Morphine Benzedrine Group score, pupillometry measurements, and safety. Thirty‐eight subjects completed the study. Chewed and intact oxycodone DETERx were bioequivalent, unlike crushed immediate‐release oxycodone, which yielded higher peak oxycodone plasma concentrations compared with all methods of oxycodone DETERx administration. The mean maximum (peak) effect (E(max)) for drug liking was significantly lower for chewed and intact oxycodone DETERx than for crushed immediate‐release oxycodone (P < .01). The time to E(max) was significantly longer for chewed and intact oxycodone DETERx than for crushed immediate‐release oxycodone (P < .0001). Scores for feeling high and Addiction Research Center Inventory/Morphine Benzedrine Group scores demonstrated lower abuse potential for chewed and intact oxycodone DETERx compared with crushed immediate‐release oxycodone. Study treatments were well tolerated; no subjects experienced serious adverse events. These results demonstrate the lower oral abuse potential of chewed and intact oxycodone DETERx than crushed immediate‐release oxycodone. |
format | Online Article Text |
id | pubmed-5363337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53633372017-04-06 Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) Kopecky, Ernest A. Fleming, Alison B. Levy‐Cooperman, Naama O'Connor, Melinda M. Sellers, Edward J Clin Pharmacol Drug Abuse Deterrence Oxycodone DETERx(®) (Collegium Pharmaceutical Inc, Canton, Massachusetts) is an extended‐release, microsphere‐in‐capsule, abuse‐deterrent formulation designed to retain its extended‐release properties after tampering (eg, chewing/crushing). This randomized, double‐blind, placebo‐controlled, triple‐dummy study evaluated the oral abuse potential of intact and chewed oxycodone DETERx capsules compared with crushed immediate‐release oxycodone. Subjects with a history of recreational opioid use who were nondependent/nontolerant to opioids were enrolled. Treatments included intact oxycodone DETERx (high‐fat, high‐calorie meal and fasted), chewed oxycodone DETERx (high‐fat, high‐calorie meal and fasted), crushed immediate‐release oxycodone (fasted), and placebo (high‐fat, high‐calorie meal). Plasma samples were collected to determine pharmacokinetic parameters. The primary endpoint was drug liking at the moment; other endpoints included drug effects questionnaire scores, Addiction Research Center Inventory/Morphine Benzedrine Group score, pupillometry measurements, and safety. Thirty‐eight subjects completed the study. Chewed and intact oxycodone DETERx were bioequivalent, unlike crushed immediate‐release oxycodone, which yielded higher peak oxycodone plasma concentrations compared with all methods of oxycodone DETERx administration. The mean maximum (peak) effect (E(max)) for drug liking was significantly lower for chewed and intact oxycodone DETERx than for crushed immediate‐release oxycodone (P < .01). The time to E(max) was significantly longer for chewed and intact oxycodone DETERx than for crushed immediate‐release oxycodone (P < .0001). Scores for feeling high and Addiction Research Center Inventory/Morphine Benzedrine Group scores demonstrated lower abuse potential for chewed and intact oxycodone DETERx compared with crushed immediate‐release oxycodone. Study treatments were well tolerated; no subjects experienced serious adverse events. These results demonstrate the lower oral abuse potential of chewed and intact oxycodone DETERx than crushed immediate‐release oxycodone. John Wiley and Sons Inc. 2016-11-01 2017-04 /pmc/articles/PMC5363337/ /pubmed/27669664 http://dx.doi.org/10.1002/jcph.833 Text en © 2016, The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Drug Abuse Deterrence Kopecky, Ernest A. Fleming, Alison B. Levy‐Cooperman, Naama O'Connor, Melinda M. Sellers, Edward Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) |
title | Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) |
title_full | Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) |
title_fullStr | Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) |
title_full_unstemmed | Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) |
title_short | Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER) |
title_sort | oral human abuse potential of oxycodone deterx(®) (xtampza(®) er) |
topic | Drug Abuse Deterrence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363337/ https://www.ncbi.nlm.nih.gov/pubmed/27669664 http://dx.doi.org/10.1002/jcph.833 |
work_keys_str_mv | AT kopeckyernesta oralhumanabusepotentialofoxycodonedeterxxtampzaer AT flemingalisonb oralhumanabusepotentialofoxycodonedeterxxtampzaer AT levycoopermannaama oralhumanabusepotentialofoxycodonedeterxxtampzaer AT oconnormelinda oralhumanabusepotentialofoxycodonedeterxxtampzaer AT msellersedward oralhumanabusepotentialofoxycodonedeterxxtampzaer |